Thus, if miR-137 could be integrated into an exosome, iPSC-derived exosome therapy can inhibit the propagation of tau pathology and, in turn, halt the progression of Alzheimer’s disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.